Section 37
Chapter 36,273

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

Morabito, F.; Gentile, M.; Mazzone, C.; Rossi, D.; Di Raimondo, F.; Bringhen, S.; Ria, R.; Offidani, M.; Patriarca, F.; Nozzoli, C.; Petrucci, M.T.; Benevolo, G.; Vincelli, I.; Guglielmelli, T.; Grasso, M.; Marasca, R.; Baldini, L.; Montefusco, V.; Musto, P.; Cascavilla, N.; Majolino, I.; Musolino, C.; Cavo, M.; Boccadoro, M.; Palumbo, A.

Blood 118(22): 5759-5766


ISSN/ISBN: 1528-0020
PMID: 21951682
DOI: 10.1182/blood-2011-05-353995
Accession: 036272103

Download citation:  

We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP). Exclusion criteria included serum creatinine ≥ 2.5 mg/dL. In the VMPT-VT/VMP arms, severe RI (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min), moderate RI (eGFR 31-50 mL/min), and normal renal function (eGFR > 50 mL/min), were 6%/7.9%, 24.1%/24.9%, and 69.8%/67.2%, respectively. Statistically significant improvements in overall response rates and progression-free survival were observed in VMPT-VT versus VMP arms across renal cohorts, except in severe RI patients. In the VMPT group, severe RI reduced overall survival (OS). RI was reversed in 16/63 (25.4%) patients receiving VMPT-VT versus 31/77 (40.3%) receiving VMP. Multivariate analysis showed male sex (P = .022) and moderate RI (P = .003) significantly predicted RI recovery. VMP patients achieving renal response showed longer OS. In both arms, greater rates of severe hematologic adverse events were associated with RI (eGFR < 50 mL/min), however, therapy discontinuation rates were unaffected. VMPT-VT was superior to VMP for cases with normal renal function and moderate RI, whereas VMPT-VT failed to outperform VMP in patients with severe RI, although the relatively low number of cases analyzed preclude drawing definitive conclusions. VMPT-VT had no advantage in terms of RI reversal over VMP.

PDF emailed within 0-6 h: $19.90